Elutia is a medical technology company focused on humanizing medicine through drug-eluting biomaterials designed to support patient recovery and surgical outcomes. Its proprietary technology combines biologic materials with extended antibiotic release, bringing together drugs, devices, and biomatrices for implant procedures and soft-tissue reconstruction. The company aims to address challenges associated with traditional medical implants and post-surgical complications, helping surgeons use regenerative materials in complex procedures.

Elutia’s portfolio includes products for reconstruction and cardiovascular applications. SIMPLIDERM is a high-performance allograft for soft-tissue reconstruction and natural remodeling. Its cardiovascular products include ProxiCor PC, ProxiCor CTR, and VasCure, engineered extracellular matrices intended to support complex surgical repair and natural healing. The company describes its platforms as integrating biologics and advanced science to unlock the therapeutic potential of implants.

Elutia also provides product instructions for use, medical affairs and customer service contacts, and digital education through a free webinar series. Based in Gaithersburg, Maryland, the company shares corporate news, investor information, and updates for healthcare professionals and other stakeholders.